Mistletoe shots for lung-spread osteosarcoma after surgery
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests Iscador P, a mistletoe-based immunotherapy given as skin injections, to help stop or control recurrent, resected osteosarcoma that has spread to the lungs. It’s for people who already had all visible lung metastases removed and are now trying to stay in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have osteosarcoma confirmed by tissue biopsy (pathology).
- Your lung cancer came back after surgery, and all visible lung metastases were removed within the last 8 weeks.
- At least one removed lung tumor site must be confirmed as osteosarcoma metastasis under the microscope.
- You’re between 8 and under 30 years old, and you can receive under-the-skin (subcutaneous) injections.
- You must be well enough to participate (Karnofsky 60%+ if over 16, or Lansky 60%+ if 16 or under) and have life expectancy over 2 months.
- Recent cancer treatment side effects must be mostly resolved, and your blood and organ tests must be within required limits (including adequate liver, kidney, white blood cell, and platelet counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to a drug called MTP-PE for people with osteosarcoma, a type of bone cancer. It is for patients who have had surgery or other treatment to remove all visible cancer and who may benefit from this drug.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests removing the tumor with surgery first, then following up with chemotherapy. It's for people with a new, high-grade osteosarcoma in an arm or leg that hasn't spread.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Osteogenic Sarcoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.